

Company

BioComomo Inc.

Presenter


Masayuki Fukumura



□ Anti-tumor immune-enhancing agents

BC-IMA : NK cells

BC-PIV/101, BC-PIV/102 : T cells



◆ BC-IMA: mainly activates NK cells

control

BC-IMA treated




4 days after treatment

◆ BC-PIV/101, BC-POV/102: mainly activates T cells

BC-POV/101
BC-IMA + inhibitor

BC-POV/101
BC-IMA



10 days after treatment